Application of Lipoprotein-associated Phospholipase A2 in Coronary Heart Disease Patients Taking Statins

Jing TANG; Jun-chao HUANG; Ya-fei HUANG; Ming-zhu GENG; Xiao-qin MAO; Jian-ping PU

doi:10.12259/j.issn.2095-610X.S20211205

Volume 42 Issue 12

Dec. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2021 > 42(12): 6-10

Jing TANG, Jun-chao HUANG, Ya-fei HUANG, Ming-zhu GENG, Xiao-qin MAO, Jian-ping PU. Application of Lipoprotein-associated Phospholipase A2 in Coronary Heart Disease Patients Taking Statins[J]. Journal of Kunming Medical University, 2021, 42(12): 6-10. doi: 10.12259/j.issn.2095-610X.S20211205

Citation:

Jing TANG, Jun-chao HUANG, Ya-fei HUANG, Ming-zhu GENG, Xiao-qin MAO, Jian-ping PU. Application of Lipoprotein-associated Phospholipase A2 in Coronary Heart Disease Patients Taking Statins[J]. Journal of Kunming Medical University, 2021, 42(12): 6-10. doi: 10.12259/j.issn.2095-610X.S20211205

Citation:

Jing TANG, Jun-chao HUANG, Ya-fei HUANG, Ming-zhu GENG, Xiao-qin MAO, Jian-ping PU. Application of Lipoprotein-associated Phospholipase A2 in Coronary Heart Disease Patients Taking Statins[J]. Journal of Kunming Medical University, 2021, 42(12): 6-10. doi: 10.12259/j.issn.2095-610X.S20211205

PDF( 620 KB)

Application of Lipoprotein-associated Phospholipase A2 in Coronary Heart Disease Patients Taking Statins

doi: 10.12259/j.issn.2095-610X.S20211205

1.
Dept. of Clinical Laboratory，Yunnan Xinkunhua Hospital, Kunming Yunnan 650301
2.
Dept. of Clinical Laboratory，The Affiliated Hospital of Kunming University of Science and Technology/The 1st People’s Hospital of Yunnan Province，Kunming Yunnan 650031
3.
Dept .of Endocrine, Yunnan Xinkunhua Hospital, Kunming Yunnan 650301, China

Received Date: 2021-10-07
Available Online: 2021-11-16
Publish Date: 2021-12-15

Abstract

Abstract

Objective To investigate the applicability of lipoprotein-associated phospholipase A2 （Lp-PLA2） as an indicator for effectiveness in patients with coronary heart disease taking statins. Methods Retrospective analysis and cohort design were used to study 58 patients with coronary heart disease who were admitted to Xinkunhua Hospital in Yunnan province. They were divided into two groups: 29 patients with coronary heart disease who were taking statins as the observation group; 29 patients with coronary heart disease who did not take statins were the control group. There were no significant differences between the observation group and the control group in gender, age, incidence of diabetes and smoking （P > 0.05）. Lp-pla2 in the two groups was compared and analyzed, and the influence of related factors on LP-PLA2 was evaluated. Results The overall Lp-PLA2 [139.6 （94.0, 181.1） ng/mL] of the observation group is significantly lower than that of the control group [278.6 （207.0, 358.3） ng/mL] （P < 0.001）. Conclusion Lp-PLA2 can be used as an effective indicator for monitoring the efficacy of statins of ASCVD.
- Atorvastatin,
- Rosuvastatin,
- Coronary heart disease（CHD）,
- Lp-PLA2

FullText(HTML)

References(13)

References

[1]	中国心血管健康与疾病报告编写组.中国心血管健康与疾病报告2019概要 [J]. 中华老年病研究电子杂志, 2020, 7（4）: 4-15.
[2]	Bueke J E,Dennis E A. Phospholipase A2 biochemistry[J]. Cardiovascular Drugs and Therapy,2009,23(1):49-59. doi: 10.1007/s10557-008-6132-9
[3]	费菲. 最新解读《脂蛋白相关磷脂酶A2临床应用中国专家建议》——第26届长城国际心脏病学会议(GW-ICC)暨亚太心脏大会201现场回顾[J]. 中国医药科学,2015,5(21):4-8.
[4]	Wang Y,Yee A J,SirardC,et al. Sodium fluoride PET imaging as a quantitative pharmacodynamic biomarker for bone homeostasis during anti-DKK1 therapy for multiple myeloma[J]. Blood Cancer Journal,2017,7(10):615. doi: 10.1038/bcj.2017.95
[5]	Brilakis E S,Khera A,Mcguire D K,et al. Influence of race and sex on lipoprotein-associated phospholipase A2 levels:observations from the Dallas Heart Study[J]. Atherosclerosis,2008,199(1):110-115. doi: 10.1016/j.atherosclerosis.2007.10.010
[6]	Heller D J,Coxson P G,Penko J,et al. Evaluating the impact and cost-effectiveness of statin use guidelines for primary prevention of coronary heart disease and stroke[J]. Circulation,2017,136(12):1087-1098. doi: 10.1161/CIRCULATIONAHA.117.027067
[7]	张恒亮,张培,陈润,等. 脂蛋白相关磷脂酶A2水平对急性冠脉综合征患者预后的预测价值研究[J]. 实用医院临床杂志,2020,17(6):212-215.
[8]	周菊芬,蔡卫平. 动脉粥样硬化性脑梗死中的脂蛋白磷脂酶A2检测的临床价值研究[J]. 系统医学,2021,6(6):55-57.
[9]	Wang R,Wang X,Zhang E,et al. Correlation of plasma galectin-3 and plasma lipoprotein-associated phospholipase A2 with the severity and prognosis of coronary artery disease[J]. American Journal of Translational Research,2021,13(8):8997-9004.
[10]	张正生,谢冠聪,黄彩艳. 脂蛋白相关磷脂酶A2在急性冠脉综合征早期预警作用的研究[J]. 当代医学,2021,27(10):129-132. doi: 10.3969/j.issn.1009-4393.2021.10.051
[11]	姜建强. 瑞舒伐他汀与阿托伐他汀对早发冠心病急性心肌梗死患者的近期疗效[J]. 中西医结合心血管病电子杂志,2020,8(4):41.
[12]	陈颖. 瑞舒伐他汀和阿托伐他汀治疗冠心病的临床疗效及应用价值比较分析[J]. 中国保健营养,2021,31(4):276-277.
[13]	孙彦彦. 脂蛋白相关磷脂酶A2与冠心病的关系及不同剂量阿托伐他汀的治疗作用 [D]. 郑州: 郑州大学硕士论文, 2010.

Relative Articles(20)

Relative Articles

[1]	Shuangshuang XU, Wei ZHAO, Lei JIANG, Huajiang LIU, Fang WANG, Zhisheng TAN, Likun ZHOU. Correlation Between TyG Index，MHR and Coronary Lesions，Myocardial Ischemia in Patients with Coronary Heart Disease，and the Value of Combined Detection. Journal of Kunming Medical University, 2024, 45(3): 65-71. doi: 10.12259/j.issn.2095-610X.S20240310
[2]	Wenqing MIAO, Yu WANG, Xiaoli ZHAO, Nini TIAN, Liying YOU. Analysis of Differential Gene Expression and Function in Peripheral Blood of Patients with Coronary Heart Disease and Acute Myocardial Infarction. Journal of Kunming Medical University, 2022, 43(6): 25-34. doi: 10.12259/j.issn.2095-610X.S20220614
[3]	Bin LIU, Xian-gang LI, Min ZHANG, Fang ZHOU, Ren-hua LIN, Jie YANG, Liang ZHANG, Xian-kun WANG, Ya-nan PAN. Main Influencing Factors of the Second Hospitalization of Patients with Coronary Heart Disease. Journal of Kunming Medical University, 2021, 42(6): 103-109. doi: 10.12259/j.issn.2095-610X.S20210618
[4]	Dai Hai Long , Zhang Xing , Pan Yun , Feng Xiao Lan , Lu Xiang Ting , Guang Xue Feng , Yin Xiao Long . . Journal of Kunming Medical University, 2020, 41(04): 60-63.
[5]	Xu XU, Li-yong WU, Ming-li ZHOU, Guo-fu ZHU. Relationship between microRNA-146a and the Plaque Stability in Coronary Heart Disease Patients. Journal of Kunming Medical University, 2020, 41(11): 56-61. doi: 10.12259/j.issn.2095-610X.S20201119
[6]	Zhao Yi, Yan Zi Jun . A Study on the Influence of Atorvastatin for the CXCL Chemokines and Vascular Endothelial Damage Indexes of Patients with Angina Pectoris of Coronary Heart Disease. Journal of Kunming Medical University, 2018, 39(08): 59-63.
[7]	Li Lin , Li Ji Yi , Wang De Zhao , Liu Wei . 武汉地区123例冠心病患者CYP2C19基因多态性分布. Journal of Kunming Medical University, 2017, 38(06): 60-63.
[8]	Fu Zhong Yang , Yi Jing . Clinical Observation of Treatment of Hypertension and Coronary Heart Disease with Amlodipine Atorvastatin Calcium Tablet. Journal of Kunming Medical University, 2017, 38(10): 117-119.
[9]	Li Wen Hua , Wei Yun Hong , Ye Ji Yun . Effect of Probiotics on Blood Lipid Metabolism of Elderly Patients with Coronary Heart Disease. Journal of Kunming Medical University, 2016, 37(12): 82-84.
[10]	Feng Yong Hong . . Journal of Kunming Medical University,
[11]	Dai Qing Yuan . . Journal of Kunming Medical University,
[12]	Tan Xiao Bing . . Journal of Kunming Medical University,
[13]	Zhou Kai Hua . . Journal of Kunming Medical University,
[14]	Yang Ping . . Journal of Kunming Medical University,
[15]	Fu Zhong Yang . . Journal of Kunming Medical University,
[16]	Li Hong Dao . . Journal of Kunming Medical University,
[17]	Yan Wen Fei . . Journal of Kunming Medical University,
[18]	Yin Lin . . Journal of Kunming Medical University,
[19]	Lv Han Xian . Detection of Periodontopathogens in Subgingival Plaque of Patients with Coronary Heart Disease and Periodontitis. Journal of Kunming Medical University,
[20]	. . Journal of Kunming Medical University,